Reboot
Reboot Uses, Dosage, Side Effects, Food Interaction and all others data.
Reboot is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboot has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Reboot is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboot is an a-ariloxybenzyl derivative of morpholine. Reboot is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders.
| Trade Name | Reboot |
| Generic | Reboxetine |
| Reboxetine Other Names | Reboxetina, Reboxetine |
| Weight | 2mg, 4mg, , 10mg |
| Type | Tablet, Drops, Syrup |
| Formula | C19H23NO3 |
| Weight | Average: 313.397 Monoisotopic: 313.167793605 |
| Protein binding | 98% |
| Groups | Approved, Experimental |
| Therapeutic Class | |
| Manufacturer | Abbott Healthcare Pvt Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Reboot is a drug used for the acute treatment of major depression and for maintenance therapy of depression.
For the treatment of clinical depression.
Reboot is also used to associated treatment for these conditions: Major Depressive Disorder (MDD), Maintenance
How Reboot works
Reboot is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboot does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.
Toxicity
Reports of seizures (rare) have been reported
Elimination Route
Reboot is rapidly and extensively absorbed following oral administration.
Half Life
12.5 hours
Innovators Monograph
You find simplified version here Reboot
